Activated protein C resistance (FVLeiden) and thrombosis: Factor V mutations causing hypercoagulable states

Hematology/Oncology Clinics of North America

Volumn 17, Issue 1, 2003, Pages 37-61

  Nicolaes, Gerry A F ^a   Dahlbäck, Björn ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ARGININE; BLOOD CLOTTING FACTOR 5 LEIDEN; GLUTAMINE;

ACTIVATED PROTEIN C RESISTANCE; BLEEDING; BLOOD CLOTTING; BLOOD VESSEL INJURY; CARDIOVASCULAR SYSTEM; DNA DETERMINATION; GENE FREQUENCY; GENE MUTATION; GENETIC LINKAGE; GENETIC RISK; GENETIC SCREENING; HEMOSTASIS; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HYPERCOAGULABILITY; LONG TERM CARE; MOLECULAR GENETICS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RISK FACTOR; THROMBOSIS; THROMBOSIS PREVENTION;

ACTIVATED PROTEIN C RESISTANCE; FACTOR V; HUMANS; POINT MUTATION; THROMBOSIS;

EID: 0037319070     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(02)00097-7     Document Type: Review

References (156)

1. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance and regulation. Biochemistry 1991;30:10363-70.
2. Dahlbäck B. Blood coagulation. Lancet 2000;355:1627-32.
3. Dahlbäck B. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation. Semin Thromb Hemost 1999;25:273-89.
4. Colman RW, Clowes AW, George JN, et al. Overview of hemostasis. In: Colman RW, Hirsh J, Marder VJ, et al, editors. Hemostasis and thrombosis: basic principles and clinical practice. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 3-16.
5. Esmon CT. Role of coagulation inhibitors in inflammation. Thromb Haemost 2001;86:51-6.
6. Dahlbäck B, Stenflo J. A natural anticoagulant pathway: protein C,S, C4b-binding protein and thrombomodulin. In: Bloom AL, et al, editors. Haemostasis and thrombosis. London: Churchill Livingstone; 1994. p. 671-98.
7. Thomas DP. Pathogenesis of venous thrombosis. In: Bloom AL, Forbes CD, Thomas DP, editors. Haemostasis and thrombosis. Edinburgh: Churchill Livingstone; 1994. p. 1335-47.
8. Salzman EW, Hirsh J. The epidemiology, pathogenesis and natural history of venous thrombosis. In: Colman RW, Hirsh J, Marder VJ, et al, editors. Hemostasis and thrombosis: basic principles and clinical practice. Philadelphia: JB Lippincott; 1994. p. 1275-96.
9. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999;353:1167-73.
10. Anderson Jr FA, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT Study. Arch Intern Med 1991;151:933-8.
11. Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992;232:155-60.
12. Seligsohn U, Zivelin A. Thrombophilia as a multigenic disorder. Thromb Haemost 1997;78: 297-301.
13. Dahlbäck B. The protein C anticoagulant system: inherited defects as basis for venous thrombosis. Thromb Res 1995;77:1-43.
14. Bertina RM. Genetic aspects of venous thrombosis. Eur J Obstet Gynecol Reprod Biol 2001;95:189-92.
15. Morrissey JH. Tissue factor: an enzyme cofactor and a true receptor. Thromb Haemost 2001; 86:66-74.
16. Mann KG, Nesheim ME, Church WR, Haley P, Krishnaswamy S. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 1990;76:1-16.
17. Nesheim ME, Taswell JB, Mann KG. The contribution of bovine factor V and factor Va to the activity of the prothrombinase. J Biol Chem 1979;254:10952-62.
18. Rosing J, Tans G, Govers-Riemslag JWP, Zwaal RFA, Hemker HC. The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem 1980;255:274-83.
19. van Dieijen G, Tans G, Rosing J, Hemker HC. The role of phospholipid and factor VIIIa in the activation of bovine factor X. J Biol Chem 1981;256:3433-42.
20. Giesen PL, Rauch U, Bohrmann B, et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A 1999;96:2311-5.
21. Suzuki K, Dahlbäck B, Stenflo J. Thrombin-catalyzed activation of human coagulation factor V. J Biol Chem 1982;257:6556-64.
22. Nesheim ME, Foster WB, Hewick RM. Characterization of factor V activation intermediates. J Biol Chem 1984;259:3187-96.
23. Monkovic D, Tracy P. Activation of human factor V by factor Xa and thrombin. Biochemistry 1990;29:1118-28.
24. Tans G, Nicolaes GAF, Thomassen MCLGD, et al. Activation of human factor V by meizothrombin. J Biol Chem 1994;269:15969-72.
25. Ozge-Anwar AH. Slow activation of factor VIII by thrombin and other enzymes at low temperature. Scand J Haematol 1970;7:5-9.
26. Rick ME, Hoyer LW. Thrombin activation of factor VIII: the effect of inhibitors. Br J Haematol 1977;36:585-97.
27. Hultin MB, Jesty J. The activation and inactivation of human factor VIII by thrombin: effect of inhibitors of thrombin. Blood 1981;57:476-82.
28. Fulcher CA, Roberts JR, Zimmerman TS. Thrombin proteolysis of purified factor VIII procoagulant protein: correlation of activation with generation of a specific polypeptide. Blood 1983;61:807-11.
29. Jensen AH, Beguin S, Josso F. Factor V and VIII activation "in vivo" during bleeding: evidence of thrombin formation at the early stage of hemostasis. Pathol Biol (Paris) 1976; 24(suppl):6-10.
30. Vehar GA, Davie EW. Preparation and properties of bovine factor VIII (antihemophilic factor). Biochemistry 1980;19:401-10.
31. Walsh PN. Roles of platelets and factor XI in the initiation of blood coagulation by thrombin. Thromb Haemost 2001;86:75-82.
32. Minnema MC, Friederich PW, Levi M, et al. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI: in vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Invest 1998;101:10-4.
33. Swords JN, Mann KG. Thrombin. In: Colman RW, Hirsh J, Marder VJ, et al, editors. Hemostasis and thrombosis. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 171-89.
34. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000;407:258-64.
35. Bajzár L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995;270:14477-84.
36. Mosnier LO, von dem Borne PA, Meijers JC, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998;80:829-35.
37. Esmon CT, Schwarz HP. An update on clinical and basic aspects of the protein C anticoagulant pathway. Trends Cardiovasc Med 1995;5:141-8.
38. Lane D, Olds RJ, Thein SL. Antithrombin and its deficiency. In: Bloom AL, Forbes CD, Thomas DP, editors. Haemostasis and thrombosis. Edinburgh: Churchill Livingstone; 1994. p. 655-70.
39. Fuentes-Prior P, Iwanaga Y, Huber R, et al. Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex. Nature 2000;404:518-25.
40. Overduin M, de Beer T. The plot thickens: how thrombin modulates blood clotting. Nat Struct Biol 2000;7:267-9.
41. Dahlbäck B, Stenflo J. The protein C anticoagulant system. In: Stamatoyannopoulos G, Nienhuis AW, Majerus PW, editors. The molecular basis of blood diseases. Philadelphia: WB Saunders; 1994. p. 599-628.
42. Fay PJ. Factor VIII structure and function. Thromb Haemost 1993;70:63-7.
43. Kalafatis M, Rand MD, Mann G. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 1994;269:31869-80.
44. Dahlback B, Stenflo J. High molecular weight complex in human plasma between vitamin K-dependent protein S and complement component C4b-binding protein. Proc Natl Acad Sci U S A 1981;78:2512-6.
45. He X, Shen L, Villoutreix BO, Dahlback B. Amino acid residues in thrombin-sensitive region and first epidermal growth factor domain of vitamin K-dependent protein S determining specificity of the activated protein C cofactor function. J Biol Chem 1998;273:27449-58.
46. Nyberg P, Dahlback B, Garcia de Frutos P. The SHBG-like region of protein S is crucial for factor V-dependent APC cofactor function. FEBS Lett 1998;433:28-32.
47. Evenas P, Garcia de Frutos P, Nicolaes GA, Dahlback B. The second laminin G-type domain of protein S is indispensable for expression of full cofactor activity in activated protein C-catalyzed inactivation of factor Va and factor VIIIa. Thromb Haemost 2000;84:271-7.
48. Walker FJ. Regulation of activated protein C by protein S: the role of phospholipid in factor Va inactivation. J Biol Chem 1981;256:11128-31.
49. Solymoss S, Tucker MM, Tracy PB. Kinetics of inactivation of membrane-bound factor Va by activated protein C: protein S modulates factor Xa protection. J Biol Chem 1988;263: 14884-90.
50. Regan LM, Lamphear BJ, Huggins CF, Walker FJ, Fay PJ. Factor IXa protects factor VIIIa from activated protein C: factor IXa inhibits activated protein C-catalyzed cleavage of factor VIIIa at Arg562. J Biol Chem 1994;269:9445-52.
51. Nicolaes GAF, Tans G, Thomassen MCLGD, et al. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein. J Biol Chem 1995;270:21158-66.
52. R506Q by activated protein C. J Biol Chem 1995;270:27852-8.
53. Tracy PB, Eide LL, Bowie EJ. Radioimmunoassay of factor V in human plasma and platelets. Blood 1982;60:59-63.
54. Owen Jr CA, Bowie EJ. Generation of coagulation factors V, XI, and XII by the isolated rat liver. Haemostasis 1977;6:205-12.
55. Wilson DB, Salem HH, Mruk JS, Maruyama I, Majerus PW. Biosynthesis of coagulation factor V by a human hepatocellular carcinoma cell line. J Clin Invest 1984;73:654-8.
56. Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene. Nature 1984;312:326-30.
57. Kane WH, Davie EW. Blood coagulation factors Vand VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood 1988;71:539-55.
58. Jenny RJ, Pittman DD, Toole JT, et al. Complete cDNA and derived amino acid sequence of human factor V. Proc Natl Acad Sci U S A 1987;84:4846-50.
59. Church WR, Jernigan RL, Toole JT, et al. Coagulation factors V and VIII and ceruloplasmin constitute a family of structural related proteins. Proc Natl Acad Sci U S A 1984;81: 6934-7.
60. Villoutreix BO, Dahlback B. Structural investigation of the A domains of human blood coagulation factor V by molecular modeling. Protein Sci 1998;7:1317-25.
61. Villoutreix B, Bucher P, Hofmann K, Baumgartner S, Dahlback B. Molecular models for the two discoidin domains of human blood coagulation factor V. J Mol Model 1998;4:268-75.
62. Pellequer JL, Gale AJ, Griffin JH, Getzoff ED. Homology models of the C domains of blood coagulation factors V and VIII: a proposed membrane binding mode for FV and FVIII C2 domains. Blood Cells Mol Dis 1998;24:448-61.
63. Macedo-Ribeiro S, Bode W, Huber R, et al. Crystal structures of the membrane-binding C2 domain of human coagulation factor V. Nature 1999;402:434-9.
64. Pratt KP, Shen BW, Takeshima K, Davi EW, Fujikawa K, Stoddard BL. Structure of the C2 domain of human factor VIII at 1.5 A resolution. Nature 1999;402:439-42.
65. Stoylova SS, Lenting PJ, Kemball-Cook G, Holzenburg A. Electron crystallography of human blood coagulation factor VIII bound to phospholipid monolayers. J Biol Chem 1999;274: 36573-8.
66. Pellequer JL, Gale AJ, Getzoff ED, Griffin JH. Three-dimensional model of coagulation factor Va bound to activated protein C. Thromb Haemost 2000;84:849-57.
67. Rosing J, Bakker HM, Thomassen MCLGD, Hemker HC, Tans G. Characterization of two forms of human factor Va with different cofactor activities. J Biol Chem 1993;268:21130-6.
68. Kim SW, Ortel TL, Quinn-Allen MA, et al. Partial glycosylation at asparagine-2181 of the second C-type domain of human factor V modulates assembly of the prothrombinase complex. Biochemistry 1999;38:11448-54.
69. Nicolaes GA, Villoutreix BO, Dahlback B. Partial glycosylation of Asn2181 in human factor V as a cause of molecular and functional heterogeneity: modulation of glycosylation efficiency by mutagenesis of the consensus sequence for N-linked glycosylation. Biochemistry 1999;38: 13584-91.
70. Varadi K, Rosing J, Tans G, Pabinger I, Keil B, Schwarz HP. Factor V enhances the cofactor function of protein S in the APC-mediated inactivation of factor VIII: influence of the factor VR506Q mutation. Thromb Haemost 1996;76:208-14.
71. Hoekema L, Nicolaes GAF, Hemker HC, Tans G, Rosing J. Human factor Va1 and factor Va2: properties in the procoagulant and anticoagulant pathways. Biochemistry 1997;36:3331-5.
72. Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem 1994;269:18735-8.
73. Dahlbäck B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci U S A 1994; 91:1396-400.
74. Varadi K, Rosing J, Tans G, Schwarz HP. Influence of factor V and factor Va on APC-induced cleavage of human factor VIII [letter]. Thromb Haemost 1995;73:730-1.
75. Kalafatis M, Haley PE, Lu DS, Bertina RM, Long GL, Mann KG. Proteolytic events that regulate factor V activity in whole plasma from normal and activated protein C (APC)-resistant individuals during clotting: an insight into the APC-resistance assay. Blood 1996;87: 4695-707.
76. Thorelli E, Kaufman RJ, Dahlback B. The C-terminal region of the factor V B-domain is crucial for the anticoagulant activity of factor V. J Biol Chem 1998;273:16140-5.
77. Thorelli E, Kaufman RJ, Dahlback B. Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V. Blood 1999;93:2552-8.
78. Dahlbäck B. Procoagulant and anticoagulant properties of coagulation factor V: factor V Leiden (APC resistance) causes hypercoagulability by dual mechanisms. J Lab Clin Med 1999;133: 415-22.
79. Nizzi Jr FA, Kaplan HS. Protein C and S deficiency. Semin Thromb Hemost 1999;25:265-72.
80. Aiach M, Borgel D, Gaussem P, Emmerich J, Alhenc-Gelas M, Gandrille S. Protein C and protein S deficiencies. Semin Hematol 1997;34:205-16.
81. Reitsma PH. Protein C deficiency: from gene defects to disease. Thromb Haemost 1997;78: 344-50.
82. Manucci PM. The molecular basis of inherited thrombophilia. Vox Sang 2000;78(suppl 2): 39-45.
83. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993;90:1004-8.
84. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994;330:517-22.
85. Rosén S, Johansson K, Lindberg K, Dahlbäck B. Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasmas from healthy individuals: the APC Resistance Study Group. Thromb Haemost 1994;72:255-60.
86. Jorquera JI, Montoro JM, Fernández MA, Aznar JA, Aznar J. Modified test for activated protein C resistance. Lancet 1994;344:1162-3.
87. Svensson PJ, Zoller B, Dahlback B. Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls. Thromb Haemost 1997;77:332-5.
88. Hall C, Andersson NE, Andras M, Zetterberg U, Rosen S. Evaluation of a modified APTT-based method for determination of APC resistance in plasma from patients on heparin or oral anticoagulant therapy. Thromb Res 1998;89:203-9.
89. Koster T, Rosendaal FR, De Ronde H, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to a poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993;342:1503-6.
90. Griffin JH, Evatt B, Wideman C, Fernández JA. Anticoagulant protein C pathway defective in a majority of thrombophilic patients. Blood 1993;82:1989-93.
91. Zöller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994;343:1536-8.
92. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
93. Sun X, Evatt B, Griffin JH. Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia. Blood 1994;83:3120-5.
94. Greengard JS, Sun X, Xu X, Fernández JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 1994;343:1361-2.
95. 506 of factor V. Lancet 1994;343:1535-6.
96. Rees DC, Cox MJ, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133-4.
97. Martinelli I. Risk factors in venous thromboembolism. Thromb Haemost 2001;86:395-403.
98. Zivelin A, Griffin JH, Xu X, et al. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood 1997;89:397-402.
99. Zoller B, Norlund L, Leksell H, et al. High prevalence of the FVR506Q mutation causing APC resistance in a region of southern Sweden with a high incidence of venous thrombosis. Thromb Res 1996;83:475-7.
100. Mari D, Mannucci PM, Duca F, Bertolini S, Franceschi C. Mutant factor V (Arg506Gln) in healthy centenarians. Lancet 1996;347:1044.
101. Nicolaes GAF, Thomassen MCLGD, Tans G, Rosing J, Hemker HC. Effect of activated protein C on thrombin generation and on the thrombin potential in plasma of normal and APC resistant individuals. Blood Coagul Fibrinolysis 1997;8:28-38.
102. Ma AD, Abrams CS. Activated protein C resistance, factor V Leiden, and retinal vessel occlusion. Retina 1998;18:297-300.
103. Koeleman BPC, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994;84:1031-5.
104. Zöller B, Bernsdotter A, García de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995;85: 3518-23.
105. Koeleman BPC, Van Rumpt D, Hamulyák K, Reitsma PH, Bertina RM. Factor V Leiden: an additional risk factor for thrombosis in protein S deficient families. Thromb Haemost 1995; 74:580-3.
106. van Boven HH, Reitsma PH, Rosendaal FR, et al. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemost 1996;75:417-21.
107. Ehrenforth S, von Depka Prondsinski M, Aygoren-Pursun E, Nowak-Gottl U, Scharrer I, Ganser A. Study of the prothrombin gene 20201 GA variant in FV:Q506 carriers in relationship to the presence or absence of juvenile venous thromboembolism. Arterioscler Thromb Vasc Biol 1999;19:276-80.
108. Jordan WM. Pulmonary embolism. Lancet 1961;2:1147-9.
109. Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994;94:2521-4.
110. Williamson D, Brown K, Luddington R, Baglin C, Baglin T. Factor V Cambridge: a new mutation (Arg306 → Thr) associated with resistance to activated protein C. Blood 1998;91: 1140-4.
111. Chan WP, Lee CK, Kwong YL, Lam CK, Liang R. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood 1998;91:1135-9.
112. Norstrøm E, Thorelli E, Dahlbäck B. Functional characterization of recombinant Factor V Cambridge and Factor V Hong Kong. Blood 2002;100:524-30.
113. Lunghi B, Iacoviello L, Gemmati D, et al. Detection of new polymorphic markers in the factor V gene: association with factor V levels in plasma. Thromb Haemost 1996;75:45-8.
114. Bernardi F, Faioni EM, Castoldi E, et al. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood 1997;90:1552-7.
115. Alhenc-Gelas M, Nicaud V. Gandrille S, et al. The factor V gene A4070G mutation and the risk of venous thrombosis. Thromb Haemost 1999;81:193-7.
116. Faioni EM, Franchi F, Bucciarelli P, et al. Coinheritance of the HR2 haplotype in the factor V gene confers an increased risk of venous thromboembolism to carriers of factor V R506Q (factor V Leiden). Blood 1999;94:3062-6.
117. Luddington R, Jackson A, Pannerselvam S, Brown K, Baglin T. The factor V R2 allele: risk of venous thromboembolism factor V levels and resistance to activated protein C. Thromb Haemost 2000;83:204-8.
118. Siegert G, Kostka H, Gehrisch S, Schwarz T, Schellong S, Jaross W. Method-dependent influence of certain polymorphisms in the factor V B-domain on the response to activated protein C. Blood Coagul Fibrinolysis 2000;11:519-27.
119. Castoldi E, Rosing J, Girelli D, et al. Mutations in the R2 FV gene affect the ratio between the two FV isoforms in plasma. Thromb Haemost 2000;83:362-5.
120. Hoekema L, Castoldi E, Tans G, et al. Functional properties of factor V and factor Va encoded by the R2-gene. Thromb Haemost 2001;85:75-81.
121. Zehnder JL, Jain M. Recurrent thrombosis due to compound heterozygosity for factor V Leiden and factor V deficiency. Blood Coagul Fibrinolysis 1996;7:361-2.
122. Simioni P, Scudeller A, Radossi P, et al. "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds. Thromb Haemost 1996;75:422-6.
123. Guasch JF, Lensen RP, Bertina RM. Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is "pseudo homozygous" for activated protein C resistance. Thromb Haemost 1997;77:252-7.
124. Castaman G, Lunghi B, Missiaglia E, Bernardi F, Rodeghiero F. Phenotypic homozygous activated protein C resistance associated with compound heterozygosity for Arg506Gln (factor V Leiden) and His1299Arg substitutions in factor V. Br J Haematol 1997;99:257-61.
125. Delahousse B, Iochmann S, Pouplard C, Fimbel B, Charbonnier B, Gruel Y. Pseudo-homozygous activated protein C resistance due to coinheritance of heterozygous factor V Leiden mutation and type I factor V deficiency: variable expression when analyzed by different activated protein C resistance functional assays. Blood Coagul Fibrinolysis 1997;8: 503-9.
126. Lunghi B, Castoldi E, Mingozzi F, Bernardi F, Castaman G. A novel factor V null mutation detected in a thrombophilic patient with pseudo-homozygous APC resistance and in an asymptomatic unrelated subject. Blood 1998;92:1463-4.
127. Ortel TL. Clinical and laboratory manifestations of anti-factor V antibodies. J Lab Clin Med 1999;133:326-34.
128. Cumming AM, Tait RC, Fildes S, Yoong A, Keeney S, Hay CRM. Development of resistance to activated protein C during pregnancy. Br J Haematol 1995;90:725-7.
129. Olivieri O, Friso S, Manzato F, et al. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol 1995;91:465-70.
130. Daly E, Vessey MP, Hawkins MN, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996;348:977-80.
131. Bokarewa MI, Blomback M, Egberg N, Rosen S. A new variant of interaction between phospholipid antibodies and the protein C system. Blood Coagul Fibrinolysis 1994;5:37-41.
132. Ehrenforth S, Radtke KP, Scharrer I. Acquired activated protein C-resistance in patients with lupus anticoagulants. Thromb Haemost 1995;74:797-8.
133. Henkens CM, Bom VJ, van der Meer J. Lowered APC-sensitivity ratio related to increased factor VIII-clotting activity. Thromb Haemost 1995;74:1198-9.
134. Laffan MA, Manning R. The influence of factor VIII on measurement of activated protein C resistance. Blood Coagul Fibrinolysis 1996;7:761-5.
135. 506 allele, and venous thrombosis. Ann Hematol 1996;72:166-76.
136. Rosing J, Tans G. Effects of oral contraceptives on hemostasis and thrombosis. Am J Obstet Gynecol 1999;180:S375-82.
137. Harris GM, Stendt CL, Vollenhoven BJ, Gan TE, Tipping PG. Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives. Am J Hematol 1999;60: 175-80.
138. Luyer MD, Khosla S, Owen WG, Miller VM. Prospective randomized study of effects of unopposed estrogen replacement therapy on markers of coagulation and inflammation in postmenopausal women. J Clin Endocrinol Metab 2001;86:3629-34.
139. Fisher M, Fernandez JA, Ameriso SF, et al. Activated protein C resistance in ischemic stroke not due to factor V arginine506 → glutamine mutation. Stroke 1996;27:1163-6.
140. van der Bom JG, Bots ML, Haverkate F, et al. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Intern Med 1996;125:265-9.
141. Bertina RM. Laboratory diagnosis of resistance to activated protein C (Apc resistance). Thromb Haemost 1997;78:478-82.
142. Sakata T, Kario K, Katayama Y, Matsuyama T, Kato H, Miyata T. Clinical significance of activated protein C resistance as a potential marker for hypercoagulable state. Thromb Res 1996;82:235-44.
143. de Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999;93:1271-6.
144. Rosing J, Middeldorp S, Curvers J, et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomized cross-over study. Lancet 1999;354:2036-40.
145. Curvers J, Thomassen MC, Nicolaes GA, et al. Acquired APC resistance and oral contraceptives: differences between two functional tests. Br J Haematol 1999;105:88-94.
146. Reitsma PH, van der Velden PA, Vogels E, et al. Use of the direct RNA amplification technique NASBA to detect factor V Leiden, a point mutation associated with APC resistance. Blood Coagul Fibrinolysis 1996;7:659-63.
147. Liebman HA, Sutherland D, Bacon R, Mcgehee W. Evaluation of a tissue factor dependent factor V assay to detect factor V Leiden: demonstration of high sensitivity and specificity for a generally applicable assay for activated protein C resistance. Br J Haematol 1996;95: 550-3.
148. Dahlbäck B. Resistance to activated protein C as risk factor for thrombosis: molecular mechanisms, laboratory investigation, and clinical management. Semin Hematol 1997;34:217-34.
149. Toulon P, Adda R, Perez P. Sensitivity of the proc(r) global assay for protein c pathway abnormalities, clinical experience in 899 unselected patients with venous thromboembolism. Thromb Res 2001;104:93-103.
150. Nicolaes GAF, Thomassen MCLGD, Vanoerle R, et al. A prothrombinase based assay for detection of resistance to activated protein C. Thromb Haemost 1996;76:404-10.
151. Tripodi A, Mannucci PM. Laboratory investigation of thrombophilia. Clin Chem 2001;47: 1597-606.
152. Malm J, Laurell M, Nilsson IM, Dahlback B. Thromboembolic disease-critical evaluation of laboratory investigation. Thromb Haemost 1992;68:7-13.
153. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995;85:1504-8.
154. Dykes AC, Walker ID, McMahon AD, Islam SI, Tait RC. A study of protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state. Br J Haematol 2001;113:636-41.
155. Zoller B, Garcia de Frutos P, Hillarp A, Dahlback B. Thrombophilia as a multigenic disease. Haematologica 1999;84:59-70.
156. Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-7.